No title
IMPORTANCE Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy.Whether tailored dosing can improve outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy. OBJECTIVE To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early breast cancer compared with
